

A. Un-Audited Financial Results(Provisional) for the Quarter and Nine Months Ended 31st December 2011

(Rs. in Lacs)

Sr. No.	Particulars	Unaudited				Audited	
		Quarter ended		Corresponding 3 months ended in the previous year 31.12.2010	Nine Months Ended		Year Ended
		3 months ended 31.12.2011	3 months ended 30.09.2011		Year to Date figures for Current period ended 31.12.2011	Year to date figures for the previous year ended 31.12.2010	Previous accounting year ended 31.03.11
1.	Sales/Income from operation	3776.57	3871.59	3455.29	11164.43	9875.29	13135.55
2	Other Income	4.21	4.87	2.25	12.20	11.92	59.47
3	Total Income	3780.78	3876.46	3457.54	11176.63	9887.21	13195.02
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in progress	195.47	(201.83)	(430.48)	(389.51)	(199.47)	(576.27)
	(b) Consumption of raw materials	2405.24	2530.87	2810.30	7663.36	7276.27	9766.87
	(c) Employees Cost	180.42	176.00	142.79	500.65	384.81	551.64
	(d) Depreciation	91.71	102.24	93.05	275.13	241.50	327.30
	(e) Other expenditure	613.00	857.95	592.01	2089.54	1471.36	2139.16
	(f) Total	3485.84	3465.03	3207.67	10139.17	9174.47	12208.70
5	Interest	269.94	236.43	184.87	712.46	494.24	685.93
6	Profit (+) / Loss (-) from ordinary activities before tax(3)-(4+5)	25.00	175.00	65.00	325.00	218.50	300.39
7	Tax Expense	4.00	25.00	20.00	69.00	65.00	91.55
8	Profit (+) / Loss (-) from ordinary activities after tax (6-7)	21.00	150.00	45.00	256.00	153.50	208.84
9	Extraordinary Items (net of tax expense Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
10	Net Profit(+)/Loss(-) for the period (8-9)	21.00	150.00	45.00	256.00	153.50	208.84
11	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82	1317.82	1317.82
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	3041.80
13	Earning per share (EPS)						
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.15	1.14	0.34	1.94	1.16	1.58
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.15	1.14	0.34	1.94	1.16	1.58
14	Non Promoters Shareholding						
	- Number of shares	7602093	7610239	7643099	7602093	7643099	7628428
	- Percentage of shareholding	57.89	57.75	58.00	57.69	58.00	57.89
15	Promoters and Promoter group Shareholding						
	a) Pledged/ Encumbered						
	Number of Shares	1441095	3316095	3316095	1441095	3316095	3316095
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	25.84	59.56	59.91	25.84	59.91	59.75
	Percentage of Shares (as a % of the total share capital of the company)	10.94	25.16	25.16	10.94	25.16	25.16
	b) Non-encumbered						
	Number of Shares	4135060	2251914	2219054	4135060	2219054	2233727
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	74.16	40.44	40.09	74.16	40.09	40.25
	Percentage of Shares (as a % of the total share capital of the company)	31.37	17.09	16.84	31.37	16.84	16.95

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 13th February, 2012
- During the Quarter & Nine month ended 31st December 2011, 0 Investor complaint were received, all of which have been attended by the company. No complaints were pending at the beginning or at the end of the quarter.
- Previous year figure are regrouped wherever necessary.

Place: Mumbai
Date: 13.02.2012

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

Director
(Shri Govardhan M.Dhoot)

For MILWANI ASSOCIATES
Chartered Accountants



Milwani) Proprietor
Membership No.: 36099
F.R.N.:106405W

B. Segment Performance - Revenue and Results

(Rs.in Lacs)

Sr. No.	Particulars	Unaudited				Audited	
		Quarter Ended		Nine Months Ended		Year Ended	
		3 month ended 31.12.11	3 month ended 30.9.11	Correspondin g 3 months ended in the previous year 31.12.2010	Year to date figures for current period ended 31.12.11	Year to date figures for the previous year ended 31.12.10	Previous accounting year ended 31.03.11
1	Segment Revenue						
a)	Bulk Drugs	3776.57	3871.59	3317.09	11164.43	9480.29	12740.55
b)	Chemicals & Others	0.00	0.00	138.20	0.00	395.00	395.00
	Total Revenue	3776.57	3871.59	3455.29	11164.43	9875.29	13135.55
2	Segment Results						
a)	Bulk Drugs	556.02	745.45	377.81	1834.54	1031.11	1635.17
b)	Chemicals & Others	0.00	0.00	88.57	0.00	241.86	241.86
	Total Segement Results before Interest and tax	556.02	745.45	466.18	1834.54	1272.97	1877.03
	Less : i) Interest**	(269.94)	(236.43)	(184.87)	(712.46)	(494.24)	(685.93)
	(ii) Other Un-allocable Expenditure	(261.08)	(334.02)	(216.31)	(797.08)	(560.23)	(890.71)
	Total Profit Before Tax	25.00	175.00	65.00	325.00	218.50	300.39

Note:

Certain assets of the company are used by different segments for different portion of the accounting period. Hence the value of the assets cannot be allocated to the segments. Current year and Previous years figures are regrouped wherever necessary

On behalf of Board of Directors

For Mangalam Drugs & Organics Ltd.

Director
Shri. Govardhan M.Dhoot

Place: Mumbai
Date: 13th February, 2012

For MILWANI ASSOCIATES
Chartered Accountants



Rakesh K. Milwani) Proprietor
Membership No.: 36099
F.R.N.:106405W



18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel. : 22036132 / 9821162679 E-mail : rakesh_milwani@hotmail.com

To
The Secretary
Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

To,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra (E),
Mumbai - 400 051.

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at 292, Princess Street, Second Floor, Near Flyover, Mumbai - 400 002; for the quarter and nine months ended 31st December, 2011 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Mumbai

Date : 13th February, 2012.

PROPRIETOR, MILWANI ASSOCIATES